🇺🇸 FDA

Intelligence Platform

Patents

Browse 65 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11649438

Methods and compositions for treating cancer

CRISPR THERAPEUTICS AG · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11622977

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11591381

Gene-edited natural killer cells

CRISPR THERAPEUTICS AG · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11578309

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566230

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11564997

Materials and methods for treatment of friedreich ataxia and other related disorders

CRISPR THERAPEUTICS AG · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559588

Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spin

CRISPR THERAPEUTICS AG · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11529427

Gene editing for hemophilia A with improved factor VIII expression

CRISPR THERAPEUTICS AG · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497773

Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11471491

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11473060

Compositions and methods for differentiating stem cells into NK cells

CRISPR THERAPEUTICS AG · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459372

Gene-edited natural killer cells

CRISPR THERAPEUTICS AG · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11434505

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11433103

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407997

Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanin

CRISPR THERAPEUTICS AG · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11389481

Allogeneic cell therapy of B cell malignancies using genetically engineered T cells target

CRISPR THERAPEUTICS AG · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11332760

Compositions and methods for genomic editing by insertion of donor polynucleotides

CRISPR THERAPEUTICS AG · Granted Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11298378

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254912

Methods and compositions for treating cancer

CRISPR THERAPEUTICS AG · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11207351

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11202802

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11191783

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11174469

Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other relat

CRISPR THERAPEUTICS AG · Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11166985

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted